1
|
Kalinovskii AP, Utkina LL, Korolkova YV, Andreev YA. TRPV3 Ion Channel: From Gene to Pharmacology. Int J Mol Sci 2023; 24:ijms24108601. [PMID: 37239947 DOI: 10.3390/ijms24108601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 05/07/2023] [Accepted: 05/09/2023] [Indexed: 05/28/2023] Open
Abstract
Transient receptor potential vanilloid subtype 3 (TRPV3) is an ion channel with a sensory function that is most abundantly expressed in keratinocytes and peripheral neurons. TRPV3 plays a role in Ca2+ homeostasis due to non-selective ionic conductivity and participates in signaling pathways associated with itch, dermatitis, hair growth, and skin regeneration. TRPV3 is a marker of pathological dysfunctions, and its expression is increased in conditions of injury and inflammation. There are also pathogenic mutant forms of the channel associated with genetic diseases. TRPV3 is considered as a potential therapeutic target of pain and itch, but there is a rather limited range of natural and synthetic ligands for this channel, most of which do not have high affinity and selectivity. In this review, we discuss the progress in the understanding of the evolution, structure, and pharmacology of TRPV3 in the context of the channel's function in normal and pathological states.
Collapse
Affiliation(s)
- Aleksandr P Kalinovskii
- Department of Molecular Neurobiology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences (IBCh RAS), 16/10 Miklukho-Maklay Str., 117997 Moscow, Russia
| | - Lyubov L Utkina
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trbetskaya Str. 8, Bld. 2, 119991 Moscow, Russia
| | - Yuliya V Korolkova
- Department of Molecular Neurobiology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences (IBCh RAS), 16/10 Miklukho-Maklay Str., 117997 Moscow, Russia
| | - Yaroslav A Andreev
- Department of Molecular Neurobiology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences (IBCh RAS), 16/10 Miklukho-Maklay Str., 117997 Moscow, Russia
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trbetskaya Str. 8, Bld. 2, 119991 Moscow, Russia
| |
Collapse
|
2
|
Chen Y, Dong Y, Zhang Z, Han J, Chen F, Tong X, Ma H. Fra-1 induces apoptosis and neuroinflammation by targeting S100A8 to modulate TLR4 pathways in spinal cord ischemia/reperfusion injury. Brain Pathol 2023; 33:e13113. [PMID: 36634215 PMCID: PMC9836372 DOI: 10.1111/bpa.13113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 08/01/2022] [Indexed: 02/01/2023] Open
Abstract
Spinal cord ischemia/reperfusion injury (SCII) is a severe complication driven by apoptosis and neuroinflammation. An increase in the expression of c-Fos, a member of the AP-1 family, is known as a neuronal activation marker in SCII. The AP-1 family is composed of Jun, Fos, and is associated with the regulation of cytokines expression and apoptosis. Fra-1 is a member of the Fos family, however, the contribution of Fra-1 to SCII is still unclear. In our study, Fra-1 was highly upregulated especially in neurons and microglia and promoted apoptosis by changing the expression of Bax/Bcl-2 after SCII. Furthermore, we found that Fra-1 directly regulated the transcription expression of S100A8. We demonstrated that knockdown of Fra-1 alleviated S100A8 mediated neuronal apoptosis and inflammatory factor release, thus improved motor function after SCII. Interestingly, we showed that administration of TAK-242, the TLR4 inhibitor, to the ischemia/reperfusion (I/R) injury induced rats suppressed the activation of the ERK and NF-κB pathways, and further reduced Fra-1 expression. In conclusion, we found that Fra-1-targeted S100A8 was expressed the upstream of Fra-1, and the Fra-1/S100A8 interaction formed a feedback loop in the signaling pathways activated by SCII.
Collapse
Affiliation(s)
- Ying Chen
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Yan Dong
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Zai‐Li Zhang
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Jie Han
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Feng‐Shou Chen
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Xiang‐Yi Tong
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| | - Hong Ma
- Department of AnesthesiologyFirst Affiliated Hospital, China Medical UniversityShenyangLiaoningChina
| |
Collapse
|
3
|
Ranjbar H, Soti M, Razavinasab M, Kohlmeier KA, Shabani M. The neglected role of endocannabinoid actions at TRPC channels in ataxia. Neurosci Biobehav Rev 2022; 141:104860. [PMID: 36087758 DOI: 10.1016/j.neubiorev.2022.104860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Revised: 08/24/2022] [Accepted: 09/03/2022] [Indexed: 12/01/2022]
Abstract
Transient receptor potential (TRP) channels are highly expressed in cells of the cerebellum including in the dendrites and somas of Purkinje cells (PCs). Their endogenous activation promotes influx of Ca2+ and Na+, resulting in depolarization. TRP channels can be activated by endogenous endocannabinoids (eCBs) and activity of TRP channels has been shown to modulate GABA and glutamate transmission. Ataxia is caused by disruption of multiple intracellular pathways which often involve changes in Ca2+ homeostasis that can result in neural cellular dysfunction and cell death. Based on available literature, alteration of transmission of eCBs would be expected to change activity of cerebellar TRP channels. Antagonists of the endocannabinoid system (ECS) including enzymes which break eCBs down have been shown to result in reductions in postsynaptic excitatory activity mediated by TRPC channels. Further, TRPC channel antagonists could modulate both pre and postsynaptically-mediated glutamatergic and GABAergic transmission, resulting in reductions in cell death due to excitotoxicity and dysfunctions caused by abnormal inhibitory signaling. Accordingly, TRP channels, and in particular the TRPC channel, represent a potential therapeutic target for management of ataxia.
Collapse
Affiliation(s)
- Hoda Ranjbar
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Monavareh Soti
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Moazamehosadat Razavinasab
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
| | - Kristi A Kohlmeier
- Department of Drug Design and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Mohammad Shabani
- Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
| |
Collapse
|
4
|
Shirolkar P, Mishra SK. Role of TRP ion channels in pruritus. Neurosci Lett 2022; 768:136379. [PMID: 34861341 PMCID: PMC8755431 DOI: 10.1016/j.neulet.2021.136379] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Revised: 10/20/2021] [Accepted: 10/22/2021] [Indexed: 01/21/2023]
Abstract
The transient receptor potential (TRP) channel superfamily responds to various physical, chemical, and environmental stimuli including the detection of sensations both harmful and non-harmful. Among these sensations is pruritus, or itch. There are at least 27 different TRP channels and about six of them are involved in pruriception. The function of these six receptors is primarily seen in the skin and the dorsal root ganglia. Identification and biological insights provided by these receptors in pruriception is important for human health as mutations and activations of many of these channels cause discomfort and disease. This review will focus on involvement of TRP channels in pruriception that may render these channels as the targets of many antagonistic topical medications, which may help patients' better cope with the pruritus that results from various cutaneous and systemic diseases.
Collapse
Affiliation(s)
- Parth Shirolkar
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA
| | - Santosh K. Mishra
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA,Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA,The WM Keck Behavioral Center, North Carolina State University, Raleigh, NC, USA,Program in Genetics, North Carolina State University, Raleigh, NC, USA
| |
Collapse
|
5
|
Edem EE, Anyanwu CKC, Nebo KE, Akinluyi ET, Fafure AA, Ishola AO, Enye LA. Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. Psychopharmacology (Berl) 2022; 239:185-200. [PMID: 34792632 DOI: 10.1007/s00213-021-06021-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 10/26/2021] [Indexed: 11/25/2022]
Abstract
Major depressive disorder (MDD) is a serious mental disorder with influence across the functional systems of the body. The pathogenesis of MDD has been known to involve the alteration of normal body functions responsible for the normal inflammation processes within the CNS; this along with other effects results in the depreciation of the sensorimotor performance of the body. Ketamine hydrochloride, a novel antidepressant agent, has been used as a therapeutic agent to treat MDD with its efficacy stretching as far as enhancing sensorimotor performance and restoring normal cytokine levels of the CNS. While these therapeutic actions of ketamine may or may not be related, this study made use of chronic unpredictable mild stress (CUMS) to generate the mouse model of depression. The efficacy of ketamine as an antidepressant following sequential exposure and co-administrative treatment protocols of administration was evaluated using behavioural tests for sensorimotor performance and depressive-like behaviours. Its effect in managing CNS inflammation was assessed via the biochemical analysis of inflammatory cytokine levels in the cerebrum, spinal cord and cerebellum; and immunohistochemical demonstration of microglial activity in the corpus striatum and cerebellum. The sensorimotor performance which had been diminished by CUMS showed greater improvement under the sequential exposure regimen of ketamine. Ketamine was also efficacious in decreasing the level of inflammation with an evident reduction in microglial activation and pro-inflammatory cytokines in the studied regions, following CUMS exposure. Taken together, our study indicates that ketamine therapy can improve sensorimotor deficits co-morbid with a depressive disorder in parallel with modulation of the inflammatory system.
Collapse
Affiliation(s)
- Edem Ekpenyong Edem
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria.
| | - Collins-Kevin Chukwudi Anyanwu
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| | - Kate Eberechukwu Nebo
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| | - Elizabeth Toyin Akinluyi
- Neuropharmacology Unit, Department of Pharmacology and Therapeutics, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| | - Adedamola Adediran Fafure
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| | - Azeez Olakunle Ishola
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
- Neuropharmacology Unit, Department of Pharmacology and Therapeutics, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| | - Linus Anderson Enye
- Neuroscience Unit, Department of Human Anatomy, College Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, P.M.B. 5454, Ado-Ekiti, Ekiti, Nigeria
| |
Collapse
|
6
|
Bischof M, Olthoff S, Glas C, Thorn-Seshold O, Schaefer M, Hill K. TRPV3 endogenously expressed in murine colonic epithelial cells is inhibited by the novel TRPV3 blocker 26E01. Cell Calcium 2020; 92:102310. [PMID: 33161279 DOI: 10.1016/j.ceca.2020.102310] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 10/05/2020] [Accepted: 10/19/2020] [Indexed: 12/11/2022]
Abstract
TRPV3 is a Ca2+-permeable cation channel, prominently expressed by keratinocytes where it contributes to maintaining the skin barrier, skin regeneration, and keratinocyte differentiation. However, much less is known about its physiological function in other tissues and there is still a need for identifying novel and efficient TRPV3 channel blockers. By screening a compound library, we identified 26E01 as a novel TRPV3 blocker. 26E01 blocks heterologously expressed TRPV3 channels overexpressed in HEK293 cells as assessed by fluorometric intracellular free Ca2+ assays (IC50 = 8.6 μM) but does not affect TRPV1, TRPV2 or TRPV4 channels. Electrophysiological whole-cell recordings confirmed the reversible block of TRPV3 currents by 26E01, which was also effective in excised inside-out patches, hinting to a rather direct mode of action. 26E01 suppresses endogenous TRPV3 currents in the mouse 308 keratinocyte cell line and in the human DLD-1 colon carcinoma cell line (IC50 = 12 μM). In sections of the gastrointestinal epithelium of mice, the expression of TRPV3 mRNA follows a gradient along the gastrointestinal tract, with the highest expression in the distal colon. 26E01 efficiently attenuates 2-aminoethoxydiphenyl borate-induced calcium influx in primary colonic epithelial cells isolated from the distal colon. As 26E01 neither shows toxic effects on DLD-1 cells at concentrations of up to 100 μM in MTT assays nor on mouse primary colonic crypts as assessed by calcein-AM/propidium iodide co-staining, it may serve as a useful tool to further study the physiological function of TRPV3 in various tissues.
Collapse
Affiliation(s)
- Maria Bischof
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Universität Leipzig, Leipzig, Germany
| | - Stefan Olthoff
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Universität Leipzig, Leipzig, Germany
| | - Carina Glas
- Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University of Munich, Munich, Germany
| | - Oliver Thorn-Seshold
- Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians University of Munich, Munich, Germany
| | - Michael Schaefer
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Universität Leipzig, Leipzig, Germany
| | - Kerstin Hill
- Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Universität Leipzig, Leipzig, Germany.
| |
Collapse
|
7
|
Therapeutic potential of pharmacological agents targeting TRP channels in CNS disorders. Pharmacol Res 2020; 159:105026. [PMID: 32562815 DOI: 10.1016/j.phrs.2020.105026] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 05/21/2020] [Accepted: 06/11/2020] [Indexed: 02/07/2023]
Abstract
Central nervous system (CNS) disorders like Alzheimer's disease (AD), Parkinson disease (PD), stroke, epilepsy, depression, and bipolar disorder have a high impact on both medical and social problems due to the surge in their prevalence. All of these neuronal disorders share some common etiologies including disruption of Ca2+ homeostasis and accumulation of misfolded proteins. These misfolded proteins further disrupt the intracellular Ca2+ homeostasis by disrupting the activity of several ion channels including transient receptor potential (TRP) channels. TRP channel families include non-selective Ca2+ permeable channels, which act as cellular sensors activated by various physio-chemical stimuli, exogenous, and endogenous ligands responsible for maintaining the intracellular Ca2+ homeostasis. TRP channels are abundantly expressed in the neuronal cells and disturbance in their activity leads to various neuronal diseases. Under the pathological conditions when the activity of TRP channels is perturbed, there is a disruption of the neuronal homeostasis through increased inflammatory response, generation of reactive oxygen species, and mitochondrial dysfunction. Therefore, there is a potential of pharmacological interventions targeting TRP channels in CNS disorders. This review focuses on the role of TRP channels in neurological diseases; also, we have highlighted the current insights into the pharmacological modulators targeting TRP channels.
Collapse
|